Diagnostic Approach to Distinguish Renal Amyloidosis from Myeloma Kidney

1. Required Biopsy Modalities

Kidney biopsy that includes sufficient tissue for light microscopy, immunofluorescence, and electron microscopy is essential to differentiate renal amyloidosis from light‑chain cast nephropathy. 1
The combination of Congo red staining, immunofluorescence for light‑chain restriction, and electron microscopy provides the definitive diagnostic method. [1][2]

Renal Amyloidosis: Shows amorphous, eosinophilic deposits in glomeruli, interstitium, tubular basement membranes, and vessel walls; deposits appear homogeneous and acellular. [1][2]
Congo Red Staining: Produces apple‑green birefringence under polarized light in amyloid deposits. [1][3]

Amyloid: Randomly arranged, non‑branching fibrils 8–12 nm in diameter, located extracellularly in the mesangium, basement membranes, or interstitium. [1][2]
Myeloma Kidney (Cast Nephropathy): Lacks organized fibrils; casts appear as electron‑dense, amorphous material within tubular lumens. 2

Immunofluorescence is required in both conditions to demonstrate monoclonal light‑chain restriction (κ or λ dominance). [1][3]
When routine immunofluorescence is negative or equivocal, pronase digestion of paraffin‑embedded tissue can unmask hidden light‑chain deposits. 3

Laser‑microdissection followed by liquid‑chromatography tandem mass spectrometry (LC‑MS) is the gold standard for amyloid typing when immunofluorescence is inconclusive. [1][4]
LC‑MS is necessary in approximately 15 % of renal amyloidosis cases to achieve accurate typing. 4

Recommendation	Rationale / Evidence
Perform Congo red staining on all kidney biopsies from patients with monoclonal gammopathy.	Ensures detection of intratubular amyloid that may coexist with cast nephropathy. [3]
If Congo red results are equivocal, proceed to mass spectrometry for definitive amyloid identification.	Provides accurate typing when staining is ambiguous. [3]
Electron microscopy is mandatory to confirm the presence of 8–12 nm fibrils (amyloid) versus amorphous casts (myeloma kidney).	Distinguishes organized amyloid fibrils from non‑fibrillar deposits. [1][2]
Ultrastructural immunogold labeling can be employed when standard EM and immunofluorescence are inconclusive.	Offers additional specificity for light‑chain localization. [1][2]

All facts above are extracted from peer‑reviewed sources and are presented with their corresponding citation identifiers.

Negative SSA staining on a Congo red-positive renal biopsy indicates that the amyloid deposits are not composed of Serum Amyloid A protein, effectively ruling out AA amyloidosis, according to the Kidney International guidelines 5, 6
This finding necessitates further investigation to determine the specific amyloid type, as treatment and prognosis vary significantly depending on the underlying amyloid protein, with a recommendation from Kidney International 5, 7

Standard immunofluorescence for kappa and lambda light chains should be performed, and if routine immunofluorescence is negative or equivocal, pronase digestion of paraffin-embedded tissue sections should be performed to unmask potentially hidden light chain deposits, as suggested by Kidney International 5, 8
Immunohistochemical stains for light chains may also be useful in detecting intracellular monoclonal immunoglobulins when routine studies are negative, according to Kidney International 5

Mass spectrometric analysis of laser-microdissected kidney tissue containing Congo red-positive deposits is strongly recommended to definitively type the amyloidosis when immunofluorescence/immunohistochemistry results are equivocal, as recommended by Kidney International and Praxis Medical Insights 5, 6, 8

Comprehensive evaluation for monoclonal gammopathy is essential, including serum and urine protein electrophoresis, serum and urine immunofixation, and serum free light chain analysis, as recommended by Praxis Medical Insights 8